Last reviewed · How we verify
R-EPOCH
At a glance
| Generic name | R-EPOCH |
|---|---|
| Also known as | Rituximab,Etoposide,Prednisolone,Oncovin,Cyclophosphamide,Hydroxydaunorubici |
| Sponsor | Shanghai Public Health Clinical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Improving Family Communication in Older Adults: A Pilot Randomized Controlled Trial (NA)
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (PHASE2, PHASE3)
- Tocilizumab in Lung Transplantation (PHASE2)
- Dose-Finding Study of Intranasal Insulin in Healthy Participants Insulin in Healthy Participants (PHASE1)
- Phase I PK and Safety Study of Ondansetron Inhalation Powder (PHASE1)
- Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |